NCT07165067 2025-12-29
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
AP Biosciences Inc.
Phase 1 Recruiting
Clinical Trials
22 trialsNCT02360345 2024-09-26
ONX-0801
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT06231277 2024-01-30
BH002-â… -101
Zhuhai Beihai Biotech Co., Ltd
Phase 1 Completed
NCT01948297 2020-09-09
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
Debiopharm International SA
Phase 1 Terminated
NCT04179071 2020-07-07
A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine
AstraZeneca
Phase 1 Completed
NCT02264418 2020-01-18
KIDES-203
Orion Corporation, Orion Pharma
Phase 1 Completed
NCT03333824 2019-03-25
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT03415100 2018-08-01
Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours
The Third Affiliated Hospital of Guangzhou Medical University
Phase 1 Unknown
NCT03315091 2018-04-30
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00732420 2017-11-13
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00136578 2017-09-25
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00742131 2017-07-31
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00743067 2017-07-26
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00695448 2017-07-25
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
GlaxoSmithKline
Phase 1 Terminated
NCT00742261 2017-07-07
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02215850 2016-05-17
Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
Welichem Biotech Inc.
Phase 1 Completed
NCT02056392 2015-11-09
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT01931761 2015-06-30
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
AstraZeneca
Phase 1 Completed
NCT02093728 2015-06-30
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT01974349 2014-08-13
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT02046850 2014-04-29
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT00497679 2009-05-14
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
AstraZeneca
Phase 1 Terminated